Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lupus
Pharma
AZ touts phase 3 lupus win for subcutaneous Saphnelo
AstraZeneca is looking to bring a subcutaneous version of its 2021-approved Saphnelo to more patients after nabbing a European nod last month.
Zoey Becker
Jan 6, 2026 11:44am
Roche's Gazyva tees up another lupus expansion with phase 3 win
Nov 3, 2025 11:41am
AZ's Fasenra flunks COPD trial as Saphnelo makes grade in lupus
Sep 17, 2025 11:47am
Vor Bio's surprise $4B revival deal splits investor reactions
Jun 26, 2025 10:55am
Roche's Gazyva succeeds in key lupus nephritis trial
Feb 7, 2025 11:14am
Roche's Gazyva chases new kidney disease use with phase 3 win
Sep 26, 2024 11:30am
